Cargando…

Acute Treatment Regimens for Migraine in the ED

Researchers at Children's Hospital, Boston, studied the comparative effectiveness of acute medication regimens for the prevention of ED visits with migraine.

Detalles Bibliográficos
Autor principal:	Millichap, J. Gordon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Pediatric Neurology Briefs Publishers 2015
Materias:	Headache Disorders
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747262/ https://www.ncbi.nlm.nih.gov/pubmed/26933565 http://dx.doi.org/10.15844/pedneurbriefs-29-3-6

Ejemplares similares

Cyclic AMP Accumulation in Migraine Induction
por: Chelse, Ana B., et al.
Publicado: (2015)

Review of Prevention for Pediatric and Adolescent Migraine
por: Qubty, William, et al.
Publicado: (2016)

Migraine, Celiac Disease and Intestinal Microbiota
por: Rahmoune, Hakim, et al.
Publicado: (2017)

Acute Migraine Therapy: New Drugs and New Approaches
por: Monteith, Teshamae S., et al.
Publicado: (2010)

Vestibular migraine
por: Silva, Viviane Passarelli Ramin, et al.
Publicado: (2022)

Chronic migraine: Genetics or environment?
por: Chalmer, Mona Ameri, et al.
Publicado: (2021)

Why are CGRP monoclonal antibodies not yet the first line treatment in migraine prevention?
por: Simioni, Caio Vinicius de Meira Grava
Publicado: (2022)

Cold extremities in migraine: a marker for vascular dysfunction in women
por: Linstra, K. M., et al.
Publicado: (2020)

Intracranial Hypertension in Children without Papilledema
por: Chelse, Ana B., et al.
Publicado: (2015)

Blunt Head Trauma and Headache
por: Chelse, Ana B., et al.
Publicado: (2015)

Pediatric Intracranial Hypertension
por: Sivaswamy, Lalitha
Publicado: (2016)

Functional connectivity changes in complex migraine aura: beyond the visual network
por: Silvestro, Marcello, et al.
Publicado: (2021)

Multinational descriptive analysis of the real‐world burden of headache using the Migraine Buddy application
por: Goadsby, Peter J., et al.
Publicado: (2021)

It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine
por: Kubota, Gabriel Taricani
Publicado: (2022)

Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trial
por: Ashina, Messoud, et al.
Publicado: (2021)

Maintenance of response and predictive factors of 1‐year GalcanezumAb treatment in real‐life migraine patients in Italy: The multicenter prospective cohort GARLIT study
por: Vernieri, Fabrizio, et al.
Publicado: (2022)

Erenumab in chronic migraine: Experience from a UK tertiary centre and comparison with other real‐world evidence
por: Khalil, Modar, et al.
Publicado: (2022)

Review of Acute Treatment of Migraine Trial Results With the New FDA Endpoints: Design Implications for Future Trials
por: Hindiyeh, Nada A., et al.
Publicado: (2019)

Safety and efficacy of remote electrical neuromodulation for the acute treatment of chronic migraine: an open-label study
por: Grosberg, Brian, et al.
Publicado: (2021)

Headache as an acute and post‐COVID‐19 symptom in COVID‐19 survivors: A meta‐analysis of the current literature
por: Fernández‐de‐las‐Peñas, César, et al.
Publicado: (2021)

First‐line steroid treatment for spontaneous intracranial hypotension
por: Tonello, Simone, et al.
Publicado: (2022)

Basic Considerations for the Use of Monoclonal Antibodies in Migraine
por: Levin, Morris, et al.
Publicado: (2018)

Treatment with the monoclonal calcitonin gene‐related peptide receptor antibody erenumab: A real‐life study
por: de Vries Lentsch, Simone, et al.
Publicado: (2021)

Preliminary results of a withdrawal and detoxification therapeutic regimen in patients with probable chronic migraine and probable medication overuse headache
por: Trucco, M., et al.
Publicado: (2005)

Ketogenic Diet as Preferred Treatment of FIRES
por: Millichap, John J., et al.
Publicado: (2015)

Habituation of single CO(2) laser–evoked responses during interictal phase of migraine
por: de Tommaso, M., et al.
Publicado: (2005)

Visual snow syndrome, the spectrum of perceptual disorders, and migraine as a common risk factor: A narrative review
por: Klein, Antonia, et al.
Publicado: (2021)

Headaches and obesity
por: Fortini, Ida, et al.
Publicado: (2022)

Update on Idiopathic Intracranial Hypertension Management
por: Souza, Marcio Nattan Portes, et al.
Publicado: (2022)

Clinic and genetic predictors in response to erenumab
por: Zecca, Chiara, et al.
Publicado: (2022)

Behavioural intervention in medication overuse headache: A concealed double‐blind randomized controlled trial
por: Pijpers, Judith A., et al.
Publicado: (2022)

A narrative review of the calcitonin peptide family and associated receptors as migraine targets: Calcitonin gene‐related peptide and beyond
por: Garelja, Michael L., et al.
Publicado: (2022)

Preventive non–pharmacological treatment and nitric oxide in chronic migraine
por: Ciancarelli, I., et al.
Publicado: (2005)

Preventing chronicity of migraine
por: Fanciullacci, M., et al.
Publicado: (2005)

The History of the Migraine Trust
por: Rose, F. C.
Publicado: (2006)

Migraine in the emergency department: a psychometric study of a migraine “repeaters” sample
por: Villani, V., et al.
Publicado: (2005)

Improved Osteoarthritis during Erenumab Treatment for Migraine: A Case Report
por: Jantzen, Frederik Thal, et al.
Publicado: (2023)

Acute Flaccid Myelitis Outbreak
por: Millichap, J. Gordon
Publicado: (2015)

Neuropsychological-EEG Activation in Genetic Generalized Epilepsy
por: Millichap, J. Gordon, et al.
Publicado: (2015)

Diurnal and Seasonal Occurrence of Febrile Seizures
por: Millichap, John J., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_4q8p9pjjj2u56e88ettpinqnaa